To request a sample copy / brochure of this report, please visit this– https://www.rootsanalysis.com/reports/281/request-sample.html
Key Questions Answered
- Who are the leading developers of microbiome therapeutics and diagnostic tests?
- What are the key technology platforms (available / under development) for microbiome-related therapies and diagnostics?
- What are the disease indications against which microbiome-based therapeutics are being evaluated?
- Which companies are targeting gut-brain axis for the development of microbiome therapies?
- Who are the leading (industry and non-industry) players involved in the development of FMT products?
- Who are the key contract research / manufacturing service providers in this domain?
- What is the trend in capital investments in microbiome-related R&D?
- What are the contributions of big pharma players in this domain?
- Which are the popular players offering big data-related services / tools to support microbiome research?
- How is the current and future market opportunity for microbiome-based therapeutics and diagnostics is likely to be distributed across key market segments?
The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:
Type of Therapy (Tx)
Prescription Drug
Prebiotics
Probiotics
Type of Molecule (Tx)
Small Molecules
Biologics
Target Indication (Tx+Dx)
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Crohn’s Disease
Diabetes
Irritable Bowel Syndrome
Lactose Intolerance
Lung Cancer
Nonalcoholic steatohepatitis (NASH)
Obesity
Ulcerative colitis
Therapeutic Area (Tx+Dx)
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others
Key Geographical Regions (Tx+Dx)
North America
Europe
Asia-Pacific and Rest of the World
The report features inputs from eminent industry stakeholders, according to whom innovation in microbiome-related research is mostly being driven by start-ups / small-sized companies. The report includes detailed transcripts of discussions held with the following experts:
Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome)
Lee Jones (President and Chief Executive Officer, Rebiotix)
Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)
Assaf Oron (Chief Business Officer, BiomX)
Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra)
Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics)
James Burges (Executive Director, OpenBiome)
JP Benya (Vice President, Business Development, Assembly Biosciences)
Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)
The research covers detailed profiles, featuring a brief company overview, its financial information (if available), product portfolio details (such as status of development of pipeline candidates, clinical trial information and analysis of key trial end-points), recent developments and an informed future outlook.
- 4D Pharma
- Armata Pharmaceuticals
- Evelo Biosciences
- Rebiotix (Acquired by Ferring Pharmaceuticals)
- Seres Therapeutics
- Vedanta Biosciences
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
- Antibody Drug Conjugates Market (5th Edition), 2019-2030
- Gene Therapy Market (3rd Edition), 2019 – 2030
- Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
- Synthetic Lethality-based Drugs and Targets Market, 2019-2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415